Below you'll find a list of all posts that have been tagged as “Pfizer”
July 30th, 2014 Pfizer Inc, which in May abandoned its $118 billion bid for AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals. The largest U.S. drugmaker reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines. But overall sales fell on competition …
On Wednesday, Pharmaceutical Giant Pfizer Agreed to Buy Baxter International’s Vaccines Unit Worth $635 Million The deal will give Pfizer access to Baxter’s meningitis and encephalitis vaccine. Pfizer will also get access to part of a Baxter’s production facility in Austria, where the vaccines are made. The deal is expected to be carried and closes by the end of the …
Pfizer Vaccines business is one the biggest in the world, and plays host to the best selling vaccine in the world: Prevnar 13. And despite a very small product list, Prevnar’s dominance over the pneumococcal market allows them to bring in over $4 billion a year through Prevnar 13 alone. Pfizer Vaccines are also one of two key players in the …
June 17, 2014 Pfizer Inc. announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. Each year, approximately 500,000 cases of meningococcal disease occur worldwide …
2013 shows the continued levelling out of the vaccines market with a slight drop in revenue amongst the top five when compared to 2012. This flies in the face of the optimism surrounding the vaccine industry which has been predicted to reach $48 billion by 2017, and $100 billion by 2050. But despite the £21 billion growth since 2000 to …
Public health initiative aims to increase unacceptably low adult vaccination rates May 14, 2014 The American College of Physicians (ACP), CECity, and Pfizer Inc. today announced a new initiative designed to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination and tracking adult immunization rates for quality measurement and improvement. The three …
May 9, 2014 Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer’s recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. In both studies, bivalent rLP2086 was observed to generate bactericidal responses, a measurement of functional immune response, against diverse …
Study Findings, Presented at ISPPD, Demonstrate that Prevenar 13 Can Prevent Vaccine-Type Community-Acquired Pneumonia March 12, 2014 Pfizer Inc. today presented detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the landmark study of approximately 85,000 subjects, demonstrating that Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) prevented a first episode of vaccine-type community-acquired pneumonia (CAP) in adults 65 …
February 24, 2014 Pfizer Inc. today announced that the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the landmark study of approximately 85,000 subjects evaluating the efficacy of Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 65 years of age and older, achieved its primary clinical objective and both secondary clinical objectives. CAPiTA is the largest double-blind, randomized, placebo-controlled …